Literature DB >> 11216813

Early experience with extracardiac Fontan operation.

V Alexi-Meskishvili1, S Ovroutski, I Dähnert, P E Lange, R Hetzer.   

Abstract

BACKGROUND: The extracardiac Fontan (ECFO) operation has gained more widespread use over last decade. In this article we analyze our early experience with ECFO.
METHODS: Thirty-three patients underwent ECFO at median age 4.1 years. Normothermic perfusion with the heart beating was used in 24 patients and cardioplegia in 7. Fenestration was not performed in the last 16 patients who underwent surgery without cardioplegia.
RESULTS: The hospital mortality was 6% (2 patients). Necessity or duration of inotropic support, duration of mechanical ventilation, intensive care unit and hospital stay, and incidence of prolonged pleural effusions of patients operated on without cardioplegia were shorter and the rate of complications in these patients was lower than in patients who underwent cardioplegia.
CONCLUSIONS: Our preliminary experience shows that ECFO can be performed in many patients with normothermic cardiopulmonary bypass and without cardioplegia and fenestration. Avoidance of cardioplegia seems to decrease postoperative morbidity. Incidence of early postoperative arrhythmias is low. Despite encouraging early results, longer follow-up is necessary to prove the real advantages of ECFO.

Entities:  

Mesh:

Year:  2001        PMID: 11216813     DOI: 10.1016/s0003-4975(00)02069-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Effect of Fenestration on Early Postoperative Outcome in Extracardiac Fontan Patients with Different Risk Levels.

Authors:  Fan Fan; Zhimin Liu; Shoujun Li; Tong Yi; Jun Yan; Fuxia Yan; Xu Wang; Qiang Wang
Journal:  Pediatr Cardiol       Date:  2017-01-23       Impact factor: 1.655

2.  Preserved regional atrial contractile function following extra-atrial rather than intra-atrial type Fontan operation: a tissue Doppler imaging study.

Authors:  Fatima I Lunze; Wei Hui; Mohamed Y Abd El Rahman; Vladimir Alexi-Meskishvili; Roland Hetzer; Peter E Lange; Felix Berger; Hashim Abdul-Khaliq
Journal:  Clin Res Cardiol       Date:  2007-02-15       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.